A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
Status:
Withdrawn
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
The investigators hope to improve overall median survival of patients with recurrent
Glioblastoma by investigating continuous low-dose daily Temozolomide plus or minus five
treatments of re-irradiation.